Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 evaluation of mitapivat in adults with sickle cell disease
2019-003438-18Phase 2Active
- Sponsor
- Julius Clinical
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD), sponsored by Julius Clinical. Primary endpoint: Safety of AG-348. Started Apr 2020; status: active.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-003438-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003438-18.